Highlights of This Issue

1977

SMALL MOLECULE THERAPEUTICS

Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia

Monica L. Guzman, Neng Yang, Krishan K. Sharma, Marlene Balys, Cheryl A. Corbett, Craig T. Jordan, Michael W. Becker, Ulrich Steidl, Omar Abdel-Wahab, Ross L. Levine, Guido Marcucci, Gail J. Roboz, and Duane C. Hassane

A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor–Initiating Cells and Overcomes Drug Resistance


NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas


Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma


LARGE MOLECULE THERAPEUTICS

A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

Simon Brack, Isabella Attinger-Toller, Babette Schade, Frédéric Mourlane, Kristina Klupsch, Richard Woods, Helen Hachemi, Ulrike von der Bey, Susann Koenig-Friedrich, Julian Bertschinger, and Dragom Grabulovski

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Kevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, Sabine Imhof-Jung, Gerhard Niederfellner, and Ira Pastan

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Kevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, Sabine Imhof-Jung, Gerhard Niederfellner, and Ira Pastan

FAK Inhibition Disrupts a 65 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

Isabelle Tancioni, Sean Uryu, Florian J. Sulzmaier, Nina R. Shah, Christine Lawson, Nichol L.G. Miller, Christine Jean, Xiao Lei Chen, Kristy K. Ward, and David D. Schlaepfer

Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Xue-Li Bai, Qi Zhang, Long-Yun Ye, Qi-Da Hu, Qi-Han Fu, Xiao Zhi, Wei Su, Ri-Ga Su, Tao Ma, Wei Chen, Shang-Zhi Xie, Cong-Lin Chen, and Ting-Bo Liang

Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

Grazia Ambrosini, Raya Khanin, Richard D. Carvajal, and Gary K. Schwartz

Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells

Kazuya Sugiyama, Hiroaki Kajiyama, Kiyosumi Shihata, Hong Yuan, Fumitaka Kikkawa, and Takeshi Senga

Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells

Olga Azarenko, Gregoriy Smiyun, Jeffrey Mah, Leslie Wilson, and Mary Ann Jordan

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Kevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, Sabine Imhof-Jung, Gerhard Niederfellner, and Ira Pastan

FAK Inhibition Disrupts a 65 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

Isabelle Tancioni, Sean Uryu, Florian J. Sulzmaier, Nina R. Shah, Christine Lawson, Nichol L.G. Miller, Christine Jean, Xiao Lei Chen, Kristy K. Ward, and David D. Schlaepfer

Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Xue-Li Bai, Qi Zhang, Long-Yun Ye, Qi-Da Hu, Qi-Han Fu, Xiao Zhi, Wei Su, Ri-Ga Su, Tao Ma, Wei Chen, Shang-Zhi Xie, Cong-Lin Chen, and Ting-Bo Liang

Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

Grazia Ambrosini, Raya Khanin, Richard D. Carvajal, and Gary K. Schwartz

Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells

Kazuya Sugiyama, Hiroaki Kajiyama, Kiyosumi Shihata, Hong Yuan, Fumitaka Kikkawa, and Takeshi Senga

Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells

Olga Azarenko, Gregoriy Smiyun, Jeffrey Mah, Leslie Wilson, and Mary Ann Jordan

Table of Contents

August 2014 • Volume 13 • Number 8

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Kevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, Sabine Imhof-Jung, Gerhard Niederfellner, and Ira Pastan

FAK Inhibition Disrupts a 65 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

Isabelle Tancioni, Sean Uryu, Florian J. Sulzmaier, Nina R. Shah, Christine Lawson, Nichol L.G. Miller, Christine Jean, Xiao Lei Chen, Kristy K. Ward, and David D. Schlaepfer

Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Xue-Li Bai, Qi Zhang, Long-Yun Ye, Qi-Da Hu, Qi-Han Fu, Xiao Zhi, Wei Su, Ri-Ga Su, Tao Ma, Wei Chen, Shang-Zhi Xie, Cong-Lin Chen, and Ting-Bo Liang

Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

Grazia Ambrosini, Raya Khanin, Richard D. Carvajal, and Gary K. Schwartz

Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells

Kazuya Sugiyama, Hiroaki Kajiyama, Kiyosumi Shihata, Hong Yuan, Fumitaka Kikkawa, and Takeshi Senga

Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells

Olga Azarenko, Gregoriy Smiyun, Jeffrey Mah, Leslie Wilson, and Mary Ann Jordan
COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

2104 Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Pei-Pei Kung, Ricardo Martinez, Zhou Zhu, Michael Zager, Alessandra Blasina, Isha Rymer, Jill Hallin, Meirong Xu, Christopher Carroll, John Chionis, Peter Wells, Kirk Kozminski, Jeffery Fan, Oivin Guicherit, Buwen Huang, Mei Cui, Chaoting Liu, Zhongdong Huang, Anand Sistla, Jennifer Yang, and Brion W. Murray

MODELS AND TECHNOLOGIES

2116 Biochemical Assays for the Discovery of TDP1 Inhibitors

ABOUT THE COVER

Upregulation of HER2 is a hallmark of 20% to 30% of invasive breast cancers, rendering this receptor an attractive target for cancer therapy. Based on the FDA-approved antibody pertuzumab, we have created a panel of bispecific FynomAbs that target two epitopes on HER2. Confocal laser scanning microscopy performed with HER2-positive NCI-N87 cells showed that bispecific FynomAb COVA208 was able—in contrast to pertuzumab and trastuzumab—to relocalize to the intracellular area after five hours of incubation, appearing in a punctate pattern typically seen for internalized drugs. For details, see article by Brack and colleagues on page 2030.
Molecular Cancer Therapeutics

13 (8)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/13/8

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.